CompanDx unlocks the secrets of personalised medicine. We exploit our in-house data analysis algorithms to identify patterns in healthcare datasets and apply our technology to clinical trial and medical sample data to find new disease markers.We are focused on discovery of novel biomarkers accompanying the use of targeted therapies and companion diagnostics; and data mining services to proprietary repositories. Our systematic approach relies on the pillars of personalised medicine; targeted therapeutics and companion diagnostics. We aim to provide solutions to healthcare providers, pharmaceutical, diagnostic and biotech companies.Our systematic approach relies on the pillars of personalised medicine; targeted therapeutics and companion diagnostics.CompanDx is collaborating with researchers from top-tier academic institutions, pharmaceutical and biotechnology companies developed and published a novel tool for deriving new insights from gene expression repositories;Together with researchers at J Van Geest Cancer Research Centre at Nottingham Trent University, CompanDx has developed an extensive range of analytical techniques and technologies that interrogate disease proteomes, which identify proteins of value in diagnosis, prognosis and prediction of therapeutic outcomes. The company is pursuing discovery of novel biomarkers for breast cancer, prostrate cancer, Tuberculosis, Alzheimer's, Sepsis and COPD.Our systematic application of these technologies, and in particular mass spectrometry combined with bioinformatics for analysis of the resulting large high-dimensional datasets generated, has resulted in the identification of several new biomarkers that are disease specific. We monitor complete analysis of clinical trials databases focused on enabling effective disease management and reducing the risk of trial failure by patient stratification.